Clinical Trial Detail

NCT ID NCT03689855
Title Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Ramucirumab

Age Groups: adult senior

No variant requirements are available.